Pfizer Vfend Cardiac Safety Studies Needed For Esophageal Candida Approval
This article was originally published in Pharmaceutical Approvals Monthly
Approval of Pfizer’s Vfend for treatment of esophageal candidiasis depends on completion of cardiac studies to rule out an unacceptable risk of QTc prolongation, review documents for the triazole antifungal indicate.
You may also be interested in...
Revised Vfend labeling adding an esophageal candidiasis indication includes results of an FDA-requested study showing that the antifungal increases QTc by less than 10 milliseconds.
Vfend’s marked efficacy in invasive aspergillosis makes the Pfizer antifungal attractive as an active comparator in studies for the indication, FDA review documents suggest.
Fujisawa is looking to differentiate its I.V. echinocandin antifungal agent, micafungin, from Merck’s Cancidas by indications and safety profile.